Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.36 |
| ▸ | PYGL | P06737 | 3/20 | 0.36 |
| ▸ | PYGM | P11217 | 2/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18537499 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL3412930 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL21539187 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13559216 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL18681231 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL16918679 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13010055 | 1.00 | PYGB (0.36) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12899851 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL13787598 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA | |
| SCHEMBL12929272 | 0.77 | PYGB (0.38) | PYGBPYGLPYGMOGALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024565-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2019-09-26 | — | — | US | disclosed |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC (US) | 2019-07-30 | — | — | US | disclosed |
| US-9968628-B2 | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-15 | — | — | US | disclosed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8299038-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2319856-A1 | Methods and compositions for treating hepatitis c virus | Idenix (Cayman) Limited (KY) | 2011-05-11 | — | — | EP | disclosed |
| US-20100316594-A1 | MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | UNIVERSITY OF CAGLIARI (IT) | 2010-12-16 | — | — | US | disclosed |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | IDENIX PHARMACEUTICALS, INC. | 2010-11-04 | — | — | US | disclosed |
| US-20090280084-A1 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2009-11-12 | — | — | US | disclosed |
| US-20090280086-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC | 2009-11-12 | — | — | US | disclosed |
| US-7608597-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2009129120-A2 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | RFS PHARMA, LLC (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20080280850-A1 | Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus | IDENIX PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758557-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | PYGB 1780/4885PYGL 3/4885PYGM 198/4885 |
| US-20080280850-A1 | Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus | PHOSPHO1, PNP, MTAP | PYGB 455/4885PYGL 32/4885PYGM 461/4885 |
| US-20090280086-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | PYGB 1780/4885PYGL 3/4885PYGM 198/4885 |
| US-20090280084-A1 | NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS | PNP, NUDT1, RNMT | PYGB 2341/4885PYGL 277/4885PYGM 370/4885 |
| US-20190290670-A1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | HAVCR2, HCCS, PYGL | PYGB 1780/4885PYGL 3/4885PYGM 198/4885 |
| US-20100316594-A1 | MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PYGB 1690/4885PYGL 59/4885PYGM 656/4885 |
| US-10363265-B2 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | PYGB 1780/4885PYGL 3/4885PYGM 198/4885 |
| US-20100279974-A1 | Nucleosides With Non-Natural Bases as Anti-Viral Agents | PNP, NSUN2, NME2 | PYGB 1057/4885PYGL 177/4885PYGM 1541/4885 |
| US-20210024565-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, SLC29A2 | PYGB 1752/4885PYGL 70/4885PYGM 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.